Site of pegylation and polyethylene glycol molecule size attenuate interferon-α antiviral and antiproliferative activities through the JAK/STAT signaling pathway

被引:74
作者
Grace, MJ
Lee, S
Bradshaw, S
Chapman, J
Spond, J
Cox, S
DeLorenzo, M
Brassard, D
Wylie, D
Cannon-Carlson, S
Cullen, C
Indelicato, S
Voloch, M
Bordens, R
机构
[1] Schering Plough Res Inst, Union, NJ 07083 USA
[2] Aventis Pharmaceut, Bridgewater, NJ 08807 USA
关键词
D O I
10.1074/jbc.M412134200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Therapeutic pegylated interferon-alphas (IFN-alpha) are mixtures of positional isomers that have been monopegylated at specific sites on the core IFN-alpha molecule. The pegylation results in lower in vitro specific activity associated with the core IFN-a molecule that is related to the site of pegylation and size of polyethylene glycol (PEG) attached. We prepared purified, homogeneous, positional pegylation isomers of IFN-alpha2b that were monopegylated using 5-30-kDa linear PEG molecules attached at 7 primary reactive amino acid residues: Cys(1), His(34), Lys(31), Lys(83), Lys(121), Lys(131), and Lys(134). The isomers were evaluated for STAT translocation and antiviral and antiproliferative activity. The site of pegylation strongly influenced activity relative to an IFN-a2b control. The highest residual activity was observed with the His(34) positional isomers, and the lowest was observed with the Cys(1) positional isomers. The Lys positional isomers demonstrated intermediate activity, with a general order of Lys(134) > Lys(83) similar to Lys(131) similar to Lys(121) > Lys(31). The progressive relationship between decreased activity and increased PEG size suggests that pegylation may interfere with interaction and binding of IFN-alpha to the IFNAR1-IFNAR2 heterodimeric receptor. The higher specific activity associated with the His(34) positional isomer suggests that this site may be favorable for pegylating IFN-alpha2b molecules.
引用
收藏
页码:6327 / 6336
页数:10
相关论文
共 44 条
[1]   Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].
Bailon, P ;
Palleroni, A ;
Schaffer, CA ;
Spence, CL ;
Fung, WJ ;
Porter, JE ;
Ehrlich, GK ;
Pan, W ;
Xu, ZX ;
Modi, MW ;
Farid, A ;
Berthold, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202
[2]   Differential responsiveness of a splice variant of the human type I interferon receptor to interferons [J].
Cook, JR ;
Cleary, CM ;
Mariano, TM ;
Izotova, L ;
Pestka, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (23) :13448-13453
[3]   JAK-STAT PATHWAYS AND TRANSCRIPTIONAL ACTIVATION IN RESPONSE TO IFNS AND OTHER EXTRACELLULAR SIGNALING PROTEINS [J].
DARNELL, JE ;
KERR, IM ;
STARK, GR .
SCIENCE, 1994, 264 (5164) :1415-1421
[4]   Characterization and quantitation of NF-κB nuclear translocation induced by interleukin-1 and tumor necrosis factor-α -: Development and use of a high capacity fluorescence cytometric system [J].
Ding, GJF ;
Fischer, PA ;
Boltz, RC ;
Schmidt, JA ;
Colaianne, JJ ;
Gough, A ;
Rubin, RA ;
Miller, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (44) :28897-28905
[5]  
FELIX AM, 1995, INT J PEPT PROT RES, V46, P253
[6]   HUMAN-LEUKOCYTE INTERFERON SUBTYPES HAVE DIFFERENT ANTI-PROLIFERATIVE AND ANTIVIRAL ACTIVITIES ON HUMAN-CELLS [J].
FISH, EN ;
BANERJEE, K ;
STEBBING, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 112 (02) :537-546
[7]  
FORTI RL, 1986, METHOD ENZYMOL, V119, P533
[8]   Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS) [J].
Foser, S ;
Schacher, A ;
Weyer, KA ;
Brugger, D ;
Dietel, E ;
Marti, S ;
Schreitmüller, T .
PROTEIN EXPRESSION AND PURIFICATION, 2003, 30 (01) :78-87
[9]   Pegylated interferon-α2b:: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data [J].
Glue, P ;
Fang, JWS ;
Rouzier-Panis, R ;
Raffanel, C ;
Sabo, R ;
Gupta, SK ;
Salfi, M ;
Jacobs, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :556-567
[10]   Structural and biologic characterization of pegylated recombinant IFN-α2b [J].
Grace, M ;
Youngster, S ;
Gitlin, G ;
Sydor, W ;
Xie, L ;
Westreich, L ;
Jacobs, S ;
Brassard, D ;
Bausch, J ;
Bordens, R .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (12) :1103-1115